Suitable Disk Antimicrobial Susceptibility Breakpoints Defining Salmonella enterica Serovar Typhi Isolates with Reduced Susceptibility to Fluoroquinolones by Parry, Christopher M et al.
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, Dec. 2010, p. 5201–5208 Vol. 54, No. 12
0066-4804/10/$12.00 doi:10.1128/AAC.00963-10
Copyright © 2010, American Society for Microbiology. All Rights Reserved.
Suitable Disk Antimicrobial Susceptibility Breakpoints Defining
Salmonella enterica Serovar Typhi Isolates with Reduced
Susceptibility to Fluoroquinolones†
Christopher M. Parry,1,2* Chau Tran Thuy,1 Sabina Dongol,3 Abhilasha Karkey,3 Ha Vinh,1,4
Nguyen Tran Chinh,4 Pham Thanh Duy,1 Tran Vu Thieu Nga,1 James I. Campbell,1,2
Nguyen Van Minh Hoang,1,2 Amit Arjyal,3 Zulfiqar A. Bhutta,5 Sujit K. Bhattacharya,6
Magdarina D. Agtini,7 Baiqing Dong,8 Do Gia Canh,9 Aliya Naheed,10 John Wain,11
Tran Tinh Hien,4 Buddha Basnyat,3 Leon Ochiai,12 John Clemens,12
Jeremy J. Farrar,1,2 Christiane Dolecek,1,2 and Stephen Baker1,2
The Hospital for Tropical Diseases, Wellcome Trust Major Overseas Programme, Oxford University Clinical Research Unit,
Ho Chi Minh City, Vietnam1; Centre for Tropical Diseases, University of Oxford, Oxford, United Kingdom2;
Oxford University Clinical Research Unit, Patan Academy of Health Sciences, Kathmandu, Nepal3; The
Hospital for Tropical Diseases, Ho Chi Minh City, Vietnam4; Department of Paediatrics, Aga Khan University,
Karachi, Pakistan5; National Institute of Cholera and Enteric Diseases, Kolkata, India6; National Institute of
Health Research and Development, Jakarta, Indonesia7; Guangxi Centers for Disease Control and
Prevention, Nanning, Guangxi, China8; National Institute of Hygiene and Epidemiology, Hanoi,
Vietnam9; International Centre for Diarrhoeal Disease Research, Dhaka, Bangladesh10;
Laboratory for Gastrointestinal Pathogens, HPA Centre for Infections, Colindale,
United Kingdom11; and International Vaccine Institute, Seoul, South Korea12
Received 15 July 2010/Returned for modification 18 August 2010/Accepted 4 September 2010
Infections with Salmonella enterica serovar Typhi isolates that have reduced susceptibility to ofloxacin (MIC >
0.25 g/ml) or ciprofloxacin (MIC > 0.125 g/ml) have been associated with a delayed response or clinical failure
following treatment with these antimicrobials. These isolates are not detected as resistant using current disk
susceptibility breakpoints. We examined 816 isolates of S. Typhi from seven Asian countries. Screening for nalidixic
acid resistance (MIC > 16 g/ml) identified isolates with an ofloxacin MIC of >0.25 g/ml with a sensitivity of
97.3% (253/260) and specificity of 99.3% (552/556). For isolates with a ciprofloxacin MIC of >0.125 g/ml, the
sensitivity was 92.9% (248/267) and specificity was 98.4% (540/549). A zone of inhibition of <28 mm around a 5-g
ofloxacin disc detected strains with an ofloxacin MIC of >0.25 g/ml with a sensitivity of 94.6% (246/260) and
specificity of 94.2% (524/556). A zone of inhibition of <30 mm detected isolates with a ciprofloxacin MIC of >0.125
g/ml with a sensitivity of 94.0% (251/267) and specificity of 94.2% (517/549). An ofloxacin MIC of >0.25 g/ml and
a ciprofloxacin MIC of >0.125 g/ml detected 74.5% (341/460) of isolates with an identified quinolone resistance-
inducing mutation and 81.5% (331/406) of the most common mutant (carrying a serine-to-phenylalanine mutation
at codon 83 in the gyrA gene). Screening for nalidixic acid resistance or ciprofloxacin and ofloxacin disk inhibition
zone are suitable for detecting S. Typhi isolates with reduced fluoroquinolone susceptibility.
Enteric fever is an infection caused by Salmonella enterica
serovars Typhi and Paratyphi A. These human restricted
pathogens are transmitted by the fecal-oral route, and enteric
fever is common in regions with poor standards of hygiene and
sanitation. There are 27 million new enteric fever infections
each year, of which approximately 200,000 are fatal (16). An-
timicrobials are essential for appropriate clinical manage-
ment of enteric fever, but antimicrobial resistance in S.
Typhi and S. Paratyphi A have become a problem in regions
where they are endemic (6, 8). Multiple-drug-resistant
(MDR) S. Typhi and S. Paratyphi A (resistant to chloram-
phenicol, trimethoprim-sulfamethoxazole, and ampicillin)
are particularly common in some locations in Asia and have
led to large epidemics. An MDR S. Typhi strain was respon-
sible for an outbreak in Tajikistan in the late 1990s, causing
over 24,000 infections (39).
The occurrence of MDR strains limits the options for
antimicrobial therapy of enteric fever. The current WHO
guidelines suggest that the fluoroquinolones are the optimal
group of antimicrobials for the treatment of uncomplicated
typhoid fever in adults (44). The fluoroquinolones, such as
ciprofloxacin and ofloxacin, are comparatively inexpensive
and well tolerated and in early randomized clinical trials
were very effective. However, S. Typhi and S. Paratyphi A
isolates with reduced susceptibility to fluoroquinolones have
become common in Asia and are increasingly common in
Africa (6, 8, 13, 26, 32, 37). Infections with S. Typhi strains
with elevated MICs to ciprofloxacin and ofloxacin have been
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associated with the failure of treatment with these antimi-
crobials and increased disease severity (15, 30, 33, 36, 43).
Investigations of S. Typhi with reduced susceptibility to fluo-
roquinolones has shown the association of elevated MIC with
several single-base-pair mutations in the DNA gyrase gene,
gyrA, and the topoisomerase gene, parC (4, 6, 33, 42). Further-
more, extensive genome sequencing and single nucleotide
polymorphism (SNP) investigation of S. Typhi strains have
further shown the dramatic impact of strains with gyrA muta-
tions on the population structure of this monophyletic organ-
ism (35). Genotyping studies identified at least 15 independent
gyrA mutations that have occurred within a decade and stim-
ulated clonal expansion in Asia and Africa (6, 35). These data
suggest that such strains have evolved rapidly and are main-
tained by a strong selective pressure.
The laboratory detection and identification of strains with re-
duced susceptibility to fluoroquinolones are important for the
treating clinician, but such strains are categorized as susceptible
by the current interpretive guidelines for fluoroquinolone disk
susceptibility testing (3, 11, 19). These isolates are invariably re-
sistant to nalidixic acid, and susceptibility testing with a nalidixic
acid disk has been suggested as a suitable screening method for
reduced fluoroquinolone susceptibility (11, 19). The British Soci-
ety for Antimicrobial Chemotherapy (BSAC) has recommended
that for invasive isolates of Salmonella, an MIC for reduced sus-
ceptibility to fluoroquinolones should be determined (3).
Here we have examined the relationship between gyrA and
parC mutations, nalidixic acid resistance, ofloxacin and cipro-
floxacin disk inhibition zone sizes, and MIC for a large number
of S. Typhi clinical isolates from multiple locations in Asia over
a 16-year period. We suggest disk susceptibility breakpoints for
strains with reduced susceptibility to ciprofloxacin and ofloxa-
cin, which may permit the diagnostic laboratory to detect such
isolates and aid the clinical management of enteric fever.
MATERIALS AND METHODS
S. Typhi strain collection. The S. Typhi strains used in this study were com-
prised of isolates collected as part of several independent investigations. The
majority of the strains (516 strains) were collected from randomized controlled
trials conducted between 1992 and 2002 in southern Vietnam. These trials were
conducted using a standard protocol, except for the treatment regimens used,
described in detail elsewhere (5, 7, 28, 31, 38, 40, 41). One hundred and four S.
Typhi strains were isolated as part of a randomized controlled trial (gatifloxacin
versus chloramphenicol [ISRCTN53258327]) at Patan Hospital, Kathmandu,
Nepal, for the treatment of uncomplicated enteric fever between 2006 and 2008.
The remaining S. Typhi strains (a total of 196) were collected between 2002 and
2003 as part of population-based prospective surveillance studies conducted by
multiple teams in Jakarta, Indonesia (n  27), Dhaka, Bangladesh (n  40),
Hechi City, Guang Xi, China (n  51), Kolkata, India (n  25), and Karachi,
Pakistan (n  53) (6).
A subset of the strains described above (n  100; from Vietnam, Indonesia,
China, India, and Pakistan) and a collection of contemporary S. Typhi strains from
Vietnam and India (n  375) were additionally selected for screening for gyrA, gyrB,
parC, and parE mutations. These strains are presented in the supplemental material.
Microbiological methods. The isolates were identified by standard biochemical
tests and agglutination with Salmonella-specific antisera (Murex Diagnostics,
Dartford, United Kingdom). Antimicrobial susceptibilities were tested at the
time of isolation by the modified Bauer-Kirby disk diffusion method, with
zone size interpretation based on CLSI guidelines (9, 11). Antimicrobial disks
tested were chloramphenicol (CHL) (30 g), ampicillin (AMP) (10 g),
trimethoprim-sulfamethoxazole (SXT) (1.25/23.75 g), ceftriaxone (CRO)
(30 g), ofloxacin (OFX) (5 g), and nalidixic acid (NAL) (30 g). Mueller-
Hinton agar and antimicrobial discs were purchased from Unipath, Basing-
stoke, United Kingdom.
Isolates were stored on Protect beads (Prolabs, Oxford, United Kingdom) at
20°C. The isolates were later subcultured, and the disk antimicrobial susceptibility
tests were repeated on Mueller-Hinton agar by CLSI methods for NAL (30 g),
ciprofloxacin (CIP) (5 g), and ofloxacin (OFX) (5 g). The zone of inhibited
growth for each antimicrobial was measured by three separate investigators blind to
the result of the measurements of the others. The average zone size recorded by the
three readers was calculated. The MICs for the isolates were determined by the
standard agar plate dilution method according to CLSI guidelines or by Etest
according to the manufacturer’s recommendations (AB Biodisk, Sweden) (10).
The antimicrobials evaluated were CIP (0.008 g/ml to 4 g/ml), OFX (0.008
g/ml to 4 g/ml), and NAL (0.5 g/ml to 512 g/ml). Antimicrobial powders for
the agar plate dilution MICs were purchased from Sigma, United Kingdom. The
MIC end points were read by two independent investigators, each blind to the
result determined by the other. Discrepancies were resolved by discussion. Esch-
erichia coli ATCC 25922 and Staphylococcus aureus ATCC 25923 were used as
control strains for these assays. The results were interpreted according to current
CLSI guidelines, susceptible being values of 8 g/ml for nalidixic acid, 2
g/ml for ofloxacin, and 1 g/ml for ciprofloxacin. An isolate was defined as
MDR if it was resistant to chloramphenicol, trimethoprim-sulfamethoxazole, and
ampicillin by disk susceptibility testing.
PCR amplification and sequencing of gyrA, gyrB, parC, and parE genes in S.
Typhi. DNA from the strains that were selected for PCR amplification of the
gyrA, gyrB, parC, and parE genes was extracted using the Wizard genomic DNA
purification kit (Promega) according to the manufacturer’s recommendations.
Briefly, a single colony was inoculated in 1.5 ml of Luria-Bertani broth and
incubated overnight at 37°C with shaking at 300 rpm to reach 108 CFU/ml. One
ml of the bacterial culture was transferred to a microcentrifuge tube and cen-
trifuged in a microcentrifuge at 13,000 rpm for 2 min. The supernatant was
removed, and the bacterial pellet was used for DNA extraction. The extracted
DNA was stored at 20°C until required.
Oligonucleotide primers for the amplification of the quinolone resistance-
determining regions in gyrA, gyrB, parC, and parE genes in S. Typhi were as
follows (6): gyrA, GYRA/P1 (5-TGTCCGAGATGGCCTGAAGC) and
GYRA/P2 (5-TACCGTCATAAGTTATCCACG) (annealing temperature,
55°C); gyrB, StygyrB1 (5-CAAACTGGCGGACTGTCAGG) and StygyrB2 (5-
TTCCGGCATCTGACGATAGA) (annealing temperature, 62°C); parC,
StmparC1 (5-CTATGCGATGT CAGAGCTGG) and StmparC2 (5 TAA
CAGCAGCTCGGCGTATT) (annealing temperature; 62°C); and parE,
StmparE1 (5-TCTCTTCCGATGAAGTGCTG) and StmparE2 (5 ATACGG
TATAGCGGCGGTAG) (annealing temperature, 62°C).
Predicted PCR amplicon sizes were 347 bp (gyrA), 345 bp (gyrB), 270 bp
(parC), and 240 bp (parE). PCRs were performed under the following conditions:
30 cycles of 92°C for 45 s, 55°C or 62°C (depending on the primers) for 45 s, and
extension at 74°C for 1 min, followed by a final extension step at 74°C for 2 min.
The DNA sequencing reactions were performed using the CEQ DTCS Quick
Start kit (Beckman Coulter) and was sequenced using a CEQ 8000 capillary
sequencer, and the resulting DNA sequence was analyzed using CEQuence
Investigator CEQ2000XL (Beckman Coulter). All sequences were verified,
aligned, and manipulated using Bioedit software (http://www.mbio.ncsu.edu
/BioEdit/bioedit.html). All gyrA, gyrB, parC, and parE sequences were compared
to other gyrA, gyrB, parC, and parE sequences by BLASTn at NCBI. The DNA
sequence of the various S. Typhi sequences of gyrA, gyrB, parC, and parE were
downloaded and aligned with the produced sequences.
Data analysis. Zone size interpretive criteria and interpretive discrepancy
rates were calculated by the error rate-bounded method of Metzler and DeHaan
(27). The MIC breakpoints for reduced susceptibility were 0.25 g/ml for
ofloxacin and 0.125 g/ml for ciprofloxacin. The zone size breakpoints were
adjusted until the number of false-susceptible disk diffusion test results (very
major discrepancies) and false-resistant disk tests (major discrepancies) were
held to a minimum. Guidelines for acceptable discrepancy rates were according
to the CLSI recommendation (12). Normally distributed data were compared
using the Student t test, nonnormally distributed data using the Mann-Whitney
U test, and proportions by the chi-square test. Statistical analysis was performed
using EpiInfo, version 6 (CDC, Atlanta, GA), and SPSS for Windows version
10.1 (SPSS, Inc., Chicago, IL).
RESULTS
Antimicrobial susceptibility testing of S. Typhi isolates. We
investigated 816 S. Typhi isolates collected between 1992 and
2008 from seven Asian countries: Vietnam, Nepal, Indonesia,
India, Bangladesh, Pakistan, and China. Only one isolate (the
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strain isolated on admission to the health care facility) from
each patient was included for microbiological examination and
analysis.
Of the 816 S. Typhi isolates tested, 466 (57.1%) were MDR
(resistant to chloramphenicol, ampicillin, and trimethoprim-
sulfamethoxazole), while 303/816 (37%) were fully susceptible
to chloramphenicol, ampicillin, and trimethoprim-sulfameth-
oxazole. Two hundred fifty-three of the 816 isolates (31%)
were resistant to nalidixic acid (MIC, 32 g/ml), and 4 iso-
lates had an MIC of 16 g/ml (intermediate) to nalidixic acid
but were classified as resistant according to the zone sizes from
disk susceptibility testing (13 mm). Of the 466 MDR isolates,
145 (31.1%) were additionally resistant to nalidixic acid com-
pared to 80/303 (26.4%) isolates that were fully susceptible to
chloramphenicol, ampicillin, and trimethoprim-sulfamethox-
azole (P  0.16).
All 816 S. Typhi isolates were classified as susceptible to
ciprofloxacin according to MIC testing (MIC  1 g/ml), yet
12 gave a discrepant result with disk testing. These strains
exhibited an inhibition zone size of 20 mm and were, there-
fore, classified as intermediate by disk testing. Two of the 816
S. Typhi strains were graded with intermediate resistance to
ofloxacin with an MIC of 4 g/ml but had inhibition zone sizes
of 16 mm and were, therefore, classified as susceptible.
The distribution of the MIC levels to ciprofloxacin and
ofloxacin for all 816 S. Typhi isolates is presented in Fig. 1. The
histograms of the levels of MIC to ciprofloxacin and ofloxacin
both demonstrate a bimodal distribution. The two distinct
groups are partially divided by nalidixic acid susceptibility (Fig.
1, black shading denotes resistance to nalidixic acid). The 563
isolates that were susceptible to nalidixic acid had an MIC90
(range) to ciprofloxacin of 0.03 g/ml (0.008 to 0.5 g/ml) and
of 0.06 g/ml (0.016 to 0.5 g/ml) to ofloxacin. The 253 isolates
that were resistant to nalidixic acid had an MIC90 (range) to
ciprofloxacin of 0.5 g/ml (0.064 to 1 g/ml) and to ofloxacin
of 1.0 g/ml (0.125 to 4 g/ml).
Antimicrobial susceptibility test interpretive categories of S.
Typhi to ciprofloxacin and ofloxacin. The current CLSI inter-
mediate breakpoints are 2 g/ml and 4 g/ml, respectively, for
ciprofloxacin and ofloxacin. Only 2 of the 816 strains tested had
MIC levels greater than or equal to those of the current MIC
breakpoints (Fig. 1). The MICs for nalidixic acid were com-
pared with those of ofloxacin and ciprofloxacin in scatter plots
(Fig. 2). The current interpretive breakpoints are shown in Fig.
2 as dark shading in red for ofloxacin and ciprofloxacin and in
gray for nalidixic acid. The suggested interpretive breakpoints
for reduced susceptibility are depicted by a broken line with an
arrow (Fig. 2). As predicted, there was a linear relationship
between the nalidixic acid MIC and the ofloxacin (Fig. 2a) and
ciprofloxacin MICs (Fig. 2b).
Screening strains using nalidixic acid resistance (MIC  16
g/ml) for the detection of isolates with an MIC of 0.25
g/ml for ofloxacin had a sensitivity of 97.3% (253/260) and a
specificity of 99.3% (552/556) (Fig. 2a). The number of very
major discrepancies was 7/260 (2.7%), with none more than
two dilutions above the breakpoint, and the number of major
discrepancies was 4/556 (0.7%), with none more than two di-
lutions below the breakpoint. Screening for the detection of
isolates with a ciprofloxacin MIC of 0.125 g/ml, using nali-
dixic acid resistance (MIC of 16 g/ml), was not as reliable as
that for ofloxacin, as it had a sensitivity of 92.9% (248/267) and
a specificity of 98.4% (540/549). The number of very major
discrepancies was 19/267 (7.1%), with 1/267 (0.4%) more than
two dilutions above the breakpoint, and the number of major
discrepancies was 9/549 (1.6%), with none more than two di-
lutions below the breakpoint.
We explored the relationship between the diameter of the
zone of inhibition and the MICs for ciprofloxacin and ofloxa-
cin, using 5-g disks (Fig. 3). A zone of inhibition of 28 mm
around a 5-g ofloxacin disk correlated with an MIC of 0.25
g/ml, with the least number of discrepancies (Fig. 3a). The
number of very major discrepancies was 14/260 (5.4%), with
none more than two dilutions above the breakpoint, and the
number of major discrepancies was 32/556 (5.7%), with 14/556
(2.5%) more than two dilutions below the breakpoint. A zone
of inhibition of 28 mm around a 5-g ofloxacin disc detected
strains with an ofloxacin MIC of 0.25 g/ml, with a sensitivity
of 94.6% (246/260) and a specificity of 94.2% (524/556). A
zone of inhibition of 30 mm around a 5-g ciprofloxacin disk
correlated with an MIC of 0.125 g/ml, with the least num-
FIG. 1. Fluoroquinolone MIC histograms for 816 S. Typhi isolates from Asia. Histograms showing the distribution of MICs to ofloxacin (a) and
ciprofloxacin (b) of 816 S. Typhi strains, isolated from patients with enteric fever. Each isolate used for analysis was isolated from an individual
enteric fever patient. The MICs are plotted on the x axis, and the numbers of isolates corresponding with particular MICs are plotted on the y axis.
The white proportion of the columns indicates the nalidixic acid-susceptible isolates (n  563). The black proportion of the columns indicates the
nalidixic acid-resistant isolates (n  253). Both histograms show a bimodal distribution, which is partly differentiated by nalidixic acid resistance.
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ber of discrepancies (Fig. 3b). The number of very major dis-
crepancies was 16/267 (6.0%), with 4/267 (1.5%) more than
two dilutions above the breakpoint, and the number of major
discrepancies was 32/549 (5.8%), with 22/549 (4.0%) more
than two dilutions below the breakpoint. A zone of growth
inhibition of 30 mm detected isolates with a ciprofloxacin
MIC of 0.125 g/ml, with a sensitivity of 94.0% (251/267) and
a specificity of 94.2% (517/549).
Reduced susceptibility to fluoroquinolones and gyrA, gyrB,
parC, and parE mutations. To further define the S. Typhi
population with reduced susceptibility to fluoroquinolones, we
produced PCR amplicons and then sequenced the quinolone
resistance-determining region in the gyrA, gyrB, parC, and parE
genes from a collection of 475 S. Typhi strains from Vietnam,
China, India, Indonesia, and Pakistan. One hundred of these
strains were described in the previous section, and 375 were
more recent strains from Vietnam and India. The MIC range
of these strains was 1 to 512 g/ml to nalidixic acid, 0.008 to 6
g/ml to ciprofloxacin, and 0.03 to 12 g/ml to ofloxacin. These
strains and the corresponding data from these strains are de-
scribed in the supplemental material.
Fifteen of the 475 S. Typhi strains examined by PCR and
sequencing of gyrA, gyrB, parC, and parE had no mutations in
the quinolone resistance-determining regions of any gene. No
strains had a mutation in the quinolone resistance-determining
region of gyrB or parE. Four hundred sixty strains had either a
single mutation or a combination of double or triple mutations
in the gyrA and parC genes. DNA sequencing identified seven
different amino acid substitutions: D87A, aspartic acid to as-
paragine at codon 87 in the gyrA gene; S83Y, serine to tyrosine
at codon 83 in the gyrA gene; S83F, serine to phenylalanine at
codon 83 in the gyrA gene; D87G, aspartic acid to glycine at
codon 87 in the gyrA gene; S83F/D87N, serine to phenylalanine
at codon 83 and aspartic acid to asparagine at codon 87 in the
gyrA gene; S83F/D87G, serine to phenylalanine at codon 83
and aspartic acid to glycine at codon 87 in the gyrA gene; and
S83F/D87G/S80I, serine to phenylalanine at codon 83 and
aspartic acid to glycine at codon 87 in the gyrA gene and serine
to isoleucine at codon 80 in the parC gene. The most com-
monly identified amino acid replacement was S83F, constitut-
ing (88%) 406/460 strains with a mutation, with S83Y the
second most common mutant (10%) 46/460.
We compared the MICs to ofloxacin and ciprofloxacin of the
460 strains with the seven different mutation patterns and the
15 strains with no mutation detected (Fig. 4). When grouped
into strains with and without a single mutation in the gyrA
gene, the single mutation group had significantly higher MICs
to ofloxacin (Fig. 4a) and ciprofloxacin (Fig. 4b) than those
without a mutation. The most common amino acid substitu-
tion, S83F, had mean MICs of 0.75 g/ml and 0.33 g/ml to
ofloxacin and ciprofloxacin, respectively. Figure 4 also shows
the current CLSI breakpoints and the suggested ofloxacin
breakpoint of 0.25 g/ml and ciprofloxacin breakpoint of 0.125
g/ml. An MIC of 0.25 g/ml to ofloxacin and an MIC of 0.125
g/ml to ciprofloxacin detected 74.5% (341/460) of the S.
Typhi strains with an identified fluoroquinolone resistance mu-
tation and 81.5% (331/406) of the most common S. Typhi
mutant (S83F) with reduced susceptibility to fluoroquinolones.
DISCUSSION
The increasing recognition that S. Typhi isolates with re-
duced susceptibility to ofloxacin and ciprofloxacin may lead to
treatment failure has led to calls for a revision of their break-
FIG. 2. Scatter plots relating ofloxacin and ciprofloxacin MICs to nalidixic acid MIC for 816 Asian S. Typhi isolates. Scatter plots comprised
of MIC data from 816 S. Typhi isolates from Nepal (n  104), India (n  25), Indonesia (n  27), Bangladesh (n  40), Pakistan (n  53), China
(n  51), and Vietnam (n  516). Plots show the relationship between the MIC to nalidixic acid (y axis) and the MIC to ofloxacin (a) and
ciprofloxacin (b) (x axis). The vertical and horizontal shading in each scatter plot indicates the current CLSI recommendations for breakpoints
between susceptibility (white), intermediate (light gray, nalidixic acid; light red, ofloxacin and ciprofloxacin), and resistance (dark gray, nalidixic
acid; dark red, ofloxacin and ciprofloxacin) (nalidixic acid MIC, 8 g/ml and 32 g/ml; ofloxacin MIC, 2 g/ml and 8 g/ml; and
ciprofloxacin MIC, 1 g/ml and 4 g/ml). The red broken line corresponds to the proposed MIC breakpoint identifying strains with reduced
susceptibility to fluoroquinolones (ofloxacin MIC of 0.25 g/ml and ciprofloxacin MIC of 0.125 g/ml).
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points. Breakpoints of 0.25 g/ml for ofloxacin and levofloxa-
cin and 0.125 g/ml for ciprofloxacin and gatifloxacin have
been suggested (1, 2, 14, 32). Nalidixic acid resistance and disk
susceptibility testing have both been proposed as laboratory
screening methods to detect such isolates. We have explored
the performance of these methods with a large number of
strains that are representative of S. Typhi isolates circulating in
countries in Asia where it is endemic.
Nalidixic acid resistance had a sensitivity of 96.2% and
91.8% and a specificity of 99.5% and 98.5% for the detection
FIG. 3. Scatter plots relating ofloxacin and ciprofloxacin MIC to inhibition zone diameter for 816 Asian S. Typhi isolates. Scatter plots for 816
S. Typhi isolates comparing the inhibition zone diameters using a 5-g ciprofloxacin disc (a) and a 5-g ofloxacin disc (b) (x axis) and the
corresponding MIC of ciprofloxacin (a) and ofloxacin (b) (y axis). The numbers in brackets relate to the 253 nalidixic acid-resistant isolates. The
vertical red shading in each scatter plot is the current CLSI disc zone breakpoint for resistance (ofloxacin inhibition zone diameter, 16 mm;
ciprofloxacin inhibition zone diameter, 21 mm). The horizontal red shading distinguishes strains with an MIC of 2 g/ml for ofloxacin or an
MIC of 1 g/ml for ciprofloxacin. The gray shading is the proposed breakpoint for S. Typhi isolates with reduced susceptibility (ofloxacin MIC,
0.25 g/ml; ciprofloxacin MIC, 0.125 g/ml). The red broken line corresponds with the proposed breakpoints for strains with reduced
susceptibility (ofloxacin inhibition zone diameter, 28 mm; ciprofloxacin inhibition zone diameter, 30 mm).
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of isolates with reduced susceptibility to ofloxacin and cipro-
floxacin, respectively. Alternatively, using disk sensitivity test-
ing, isolates with reduced susceptibility were detected by an
ofloxacin (5-g) disk inhibition zone diameter of 28 mm with
a sensitivity of 94.6% and specificity of 94.2% and by a cipro-
floxacin (5-g) disk inhibition zone diameter of 30 mm with
a sensitivity of 94.0% and specificity of 94.2%. Therefore, both
methods had sufficiently high sensitivity for them to be used for
screening and acceptably low levels of discrepancies (12). Disk
inhibition zone size did, however, demonstrate a slightly lower
specificity than nalidixic acid disk testing with this panel of
isolates. Similar data for the relationship between nalidixic
acid resistance and a decreased ciprofloxacin MIC have been
presented for S. Typhi isolates in the United States (14) and
India (23) and in non-S. Typhi Salmonella isolates in the
United States (14) and Finland (21). For nalidixic acid-suscep-
tible and -resistant S. Typhi isolates in India (23), the average
disk inhibition zone sizes for ciprofloxacin were greater than
those that we observed here. The non-S. Typhi study in Finland
proposed a ciprofloxacin (5-g) disk inhibition zone diameter
of 37 mm as the breakpoint (21). The sensitivity of this
approach was 100%, yet the specificity was only 51.9%.
In some isolates in this study, the nalidixic acid, ofloxacin,
and ciprofloxacin MIC results were discrepant, in that isolates
were nalidixic acid susceptible but with a reduced ofloxacin
(n  10) or ciprofloxacin susceptibility (n  22). Similar results
have been seen in other studies (13, 15, 22, 26). The clinical
significance of these isolates is unclear, as there have been
limited documented cases of infection with such strains treated
with fluoroquinolones. It is likely that isolates that are nalidixic
acid susceptible but with reduced ofloxacin and ciprofloxacin
susceptibility contain resistance mechanisms other than muta-
tions in the quinolone resistance-determining region of the
gyrA gene. Possibilities include decreased permeability, an in-
crease in active efflux, and the presence of plasmid-mediated
genes, such as the qnr genes that encode a protein that protects
the DNA gyrase from ciprofloxacin or aac(6)-Ib-cr, an amino-
glycoside-modifying enzyme with activity against ciprofloxacin
(32).
The mutations that we detected in DNA gyrase genes and
topoisomerase genes were consistent with previous reports (4,
6, 34, 42). The most common amino acid substitution detected
was S83F, which has been found to be particularly associated
with the H58 haplotype (35). This haplotype has become dom-
inant in many areas of Asia in recent years and has also been
found to have spread into Kenya in East Africa (24). Approx-
FIG. 4. The relationship of gyrA and parC mutations and the MICs to ofloxacin and ciprofloxacin in the S. Typhi strain isolated in Asia. Box
plots (boxes relate to the 25th and 75th percentiles) relating mutations in the gyrA and the parC genes (the S80I mutation is in the parC gene, and
the remainder are in the gyrA gene) to the MICs of ofloxacin (a) and ciprofloxacin (b) in 475 Asian clinical isolates of S. Typhi. The MICs to
ofloxacin and ciprofloxacin are plotted on the y axis. The MICs to ofloxacin ranged from 0.016 to 12 g/ml, and those to ciprofloxacin from 0.008
to 6 g/ml. Median values for each mutant group are indentified by a solid line in the box. Bars demonstrate the 95% confidence interval for the
groups with sufficient numbers; dots correspond to outliers. The x axis is subdivided into the eight different groups of S. Typhi strains identified
and assayed, characterized as follows: no mutations in gyrA or parC (n  15), D87A (n  2), S83Y (n  46), S83F (n  406), D87G (n  2),
S83F/D87N (n  1), S83F/D87G (n  1), and S83F/D87G/S80I (n  2). The upper broken lines indicate the current CLSI breakpoint
recommendations for ofloxacin and ciprofloxacin. The lower broken lines correspond with the proposed breakpoints for strains with reduced
susceptibility to ofloxacin and ciprofloxacin. Statistical significance was calculated between the nonmutant group and the single mutant group and
between the single mutant group and the double/triple mutant group using the Student’s t test.
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imately 20 to 25% of the isolates with a gyrA mutation had an
MIC below the suggested breakpoints of 0.25 g/ml for ofloxa-
cin and 0.125 g/ml for ciprofloxacin. The effect on the re-
sponse to fluoroquinolone treatment of infection with isolates
with a single gyrA mutation but with an MIC below the sug-
gested breakpoints is not known. It is also possible that the
isolates with a single gyrA mutation but an MIC above the
suggested breakpoint have additional resistance mechanisms
present (32).
The lack of universally observed guidelines for the detection
of S. Typhi isolates with reduced susceptibility has meant that
such isolates are frequently unrecognized by microbiology lab-
oratories. Continued use of ciprofloxacin and ofloxacin for
these infections may be driving the emergence of fully fluoro-
quinolone-resistant isolates of S. Typhi and S. Paratyphi A (20,
25, 34). Gatifloxacin, azithromycin, and ceftriaxone are better
options for treating such infections, if the isolates also demon-
strate resistance to first-line antimicrobials (7, 17, 18, 29, 31).
The use of nalidixic acid resistance as a surrogate screening
test is often confusing because it is not used for the treatment
of enteric fever. Furthermore, the emergence of nalidixic acid-
susceptible isolates with reduced ofloxacin and ciprofloxacin
susceptibility may mean that some isolates are missed. There-
fore, a straightforward solution would be to modify the S.
Typhi breakpoints to 30 mm and 28 mm for ciprofloxacin
and ofloxacin, respectively. Interpretative breakpoints for the
disk susceptibility tests with the antimicrobials actually used for
treatment will better assist clinicians in the choice of therapy
for enteric fever and will allow the collection of accurate sur-
veillance data. Our data suggest disk breakpoints of 30 mm
and 28 mm for ciprofloxacin and ofloxacin, respectively.
These breakpoints have high specificity and sensitivity, permit-
ting the detection of S. Typhi strains that have reduced sus-
ceptibility to ciprofloxacin and ofloxacin.
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